XML 48 R27.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Business Segments | 12 Months Ended
--- | ---
Mar. 31, 2024
Segment Reporting [Abstract] |
Business Segments | Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses. The tables below summarize information about our operating and reportable segments.
| Year Ended March 31, 2024
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 958,260 |  |  | $ | 167,097 |  |  |  |  | $ | 1,125,357 |
Cost of sales | 429,361 |  |  | 71,548 |  |  |  |  | 500,909 |
Gross profit | 528,899 |  |  | 95,549 |  |  |  |  | 624,448 |
Advertising and marketing | 131,494 |  |  | 21,821 |  |  |  |  | 153,315 |
Contribution margin | $ | 397,405 |  |  | $ | 73,728 |  |  |  |  | 471,133 |
Other operating expenses |  |  |  |  |  |  | 128,704 |
Operating income |  |  |  |  |  |  | $ | 342,429 |
*Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment.
| Year Ended March 31, 2023
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 973,774 |  |  | $ | 153,951 |  |  |  |  | $ | 1,127,725 |
Cost of sales | 441,844 |  |  | 60,587 |  |  |  |  | 502,431 |
Gross profit | 531,930 |  |  | 93,364 |  |  |  |  | 625,294 |
Advertising and marketing | 123,926 |  |  | 21,135 |  |  |  |  | 145,061 |
Contribution margin | $ | 408,004 |  |  | $ | 72,229 |  |  |  |  | 480,233 |
Other operating expenses** |  |  |  |  |  |  | 502,648 |
Operating loss |  |  |  |  |  |  | $ | (22,415) |
* Intersegment revenues of $4.3 million were eliminated from the North American OTC Healthcare segment. **Other operating expenses for the year ended March 31, 2023 includes a tradename impairment charge of $321.4 million and a goodwill impairment charge of $48.8 million.
| Year Ended March 31, 2022
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 967,881 |  |  | $ | 118,931 |  |  |  |  | $ | 1,086,812 |
Cost of sales | 419,162 |  |  | 47,004 |  |  |  |  | 466,166 |
Gross profit | 548,719 |  |  | 71,927 |  |  |  |  | 620,646 |
Advertising and marketing | 138,714 |  |  | 18,629 |  |  |  |  | 157,343 |
Contribution margin | $ | 410,005 |  |  | $ | 53,298 |  |  |  |  | 463,303 |
Other operating expenses |  |  |  |  |  |  | 133,384 |
Operating income |  |  |  |  |  |  | $ | 329,919 |
*Intersegment revenues of $3.0 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups.
| Year Ended March 31, 2024
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 111,996 |  |  | $ | 5,455 |  |  |  |  | $ | 117,451 |
Cough & Cold | 93,575 |  |  | 25,445 |  |  |  |  | 119,020 |
Women's Health | 217,103 |  |  | 23,318 |  |  |  |  | 240,421 |
Gastrointestinal | 160,889 |  |  | 70,721 |  |  |  |  | 231,610 |
Eye & Ear Care | 156,553 |  |  | 22,870 |  |  |  |  | 179,423 |
Dermatologicals | 123,288 |  |  | 5,814 |  |  |  |  | 129,102 |
Oral Care | 83,212 |  |  | 13,093 |  |  |  |  | 96,305 |
Other OTC | 11,644 |  |  | 381 |  |  |  |  | 12,025 |
Total segment revenues | $ | 958,260 |  |  | $ | 167,097 |  |  |  |  | $ | 1,125,357 |
| Year Ended March 31, 2023
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 116,582 |  |  | $ | 2,680 |  |  |  |  | $ | 119,262 |
Cough & Cold | 100,218 |  |  | 26,770 |  |  |  |  | 126,988 |
Women's Health | 231,754 |  |  | 19,597 |  |  |  |  | 251,351 |
Gastrointestinal | 156,957 |  |  | 69,626 |  |  |  |  | 226,583 |
Eye & Ear Care | 151,879 |  |  | 19,197 |  |  |  |  | 171,076 |
Dermatologicals | 119,822 |  |  | 3,919 |  |  |  |  | 123,741 |
Oral Care | 85,542 |  |  | 12,085 |  |  |  |  | 97,627 |
Other OTC | 11,020 |  |  | 77 |  |  |  |  | 11,097 |
Total segment revenues | $ | 973,774 |  |  | $ | 153,951 |  |  |  |  | $ | 1,127,725 |
| Year Ended March 31, 2022
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 117,868 |  |  | $ | 1,455 |  |  |  |  | $ | 119,323 |
Cough & Cold | 86,855 |  |  | 20,225 |  |  |  |  | 107,080 |
Women's Health | 249,136 |  |  | 15,373 |  |  |  |  | 264,509 |
Gastrointestinal | 152,191 |  |  | 52,368 |  |  |  |  | 204,559 |
Eye & Ear Care | 149,454 |  |  | 13,995 |  |  |  |  | 163,449 |
Dermatologicals | 117,173 |  |  | 3,213 |  |  |  |  | 120,386 |
Oral Care | 85,239 |  |  | 12,282 |  |  |  |  | 97,521 |
Other OTC | 9,965 |  |  | 20 |  |  |  |  | 9,985 |
Total segment revenues | $ | 967,881 |  |  | $ | 118,931 |  |  |  |  | $ | 1,086,812 |
Our total segment revenues by geographic area are as follows:
| Year Ended March 31,
| 2024 |  | 2023 |  | 2022
United States | $ | 886,470 |  |  | $ | 953,222 |  |  | $ | 910,106 |
Rest of world | 238,887 |  |  | 174,503 |  |  | 176,706 |
Total | $ | 1,125,357 |  |  | $ | 1,127,725 |  |  | $ | 1,086,812 |
Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
March 31, 2024 (In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Goodwill | $ | 498,936 |  |  | $ | 28,797 |  |  |  |  | $ | 527,733 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,092,853 |  |  | 74,309 |  |  |  |  | 2,167,162 |
Finite-lived | 135,932 |  |  | 17,489 |  |  |  |  | 153,421 |
Intangible assets, net | 2,228,785 |  |  | 91,798 |  |  |  |  | 2,320,583 |
Total | $ | 2,727,721 |  |  | $ | 120,595 |  |  |  |  | $ | 2,848,316 |
March 31, 2023 (In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Goodwill | $ | 498,936 |  |  | $ | 28,617 |  |  |  |  | $ | 527,553 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,092,852 |  |  | 76,050 |  |  |  |  | 2,168,902 |
Finite-lived | 154,552 |  |  | 18,439 |  |  |  |  | 172,991 |
Intangible assets, net | 2,247,404 |  |  | 94,489 |  |  |  |  | 2,341,893 |
Total | $ | 2,746,340 |  |  | $ | 123,106 |  |  |  |  | $ | 2,869,446 |
Our goodwill and intangible assets by geographic area are as follows:
| Year Ended March 31,
| 2024 |  | 2023
United States | $ | 2,727,721 |  |  | $ | 2,746,340 |
Rest of world | 120,595 |  |  | 123,106 |
Total | $ | 2,848,316 |  |  | $ | 2,869,446 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration